Rare diseases
Investigational molecules
Locations
A study testing zanidatamab combined with chemotherapy before surgery in patients with HER2-positive breast cancer
GermanyStudy evaluating HER2DX-guided treatment in patients with early-stage HER2-positive breast cancer using trastuzumab, pertuzumab and combination chemotherapy
FranceStudy to Determine the Best Dose of Zongertinib with Trastuzumab Deruxtecan or Trastuzumab Emtansine for Patients with Advanced HER2+ Metastatic Cancer
BelgiumStudy on Reducing Treatment for Patients with HER2-Positive Metastatic Breast Cancer Using Trastuzumab and Drug Combination After 2 Years of Controlled Disease
FranceStudy of ribociclib with drug combination in early breast cancer patients to test de‑escalated treatment strategies
ItalyA study of Zr89-trastuzumab PET/CT imaging and trastuzumab emtansine treatment in patients with advanced HER2-positive breast cancer
BelgiumStudy of Atezolizumab, Pertuzumab, and Trastuzumab for Patients with HER2 Positive Early High-Risk and Locally Advanced Breast Cancer
AustriaStudy of 89Zr-trastuzumab PET/CT imaging and trastuzumab emtansine treatment in patients with advanced HER2-positive breast cancer
BelgiumStudy of Tucatinib and Ado-Trastuzumab Emtansine for Patients with Advanced HER2+ Breast Cancer
BelgiumStudy on Chemotherapy-Free Treatment with Trastuzumab, Pertuzumab, and T-DM1 for Patients with HER2-Positive Early-Stage Breast Cancer
GermanyStudy of Dabrafenib and Drug Combination for Patients with Metastatic Non-Clear Cell Kidney Cancer
DenmarkStudy of Trastuzumab, Pertuzumab, and Chemotherapy Combination with Response-Guided Treatment for Patients with HER2-Positive Breast Cancer
The NetherlandsTell us about your condition – we search every trial in Europe and connect you with the right site.
